Research programme: anti-infectives - Emergent BioSolutions

Drug Profile

Research programme: anti-infectives - Emergent BioSolutions

Alternative Names: 2-pyridone based topoisomerase inhibitors (EV-035); EV 035 series - Emergent BioSolutions; EV-021; EV-035; EV-035a; EV-035b; EV-035c; EV-075; EV-086; GC-0146; GC-061; GC-063; GC-072

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Evolva Biotech
  • Developer Evolva Holding SA; United States Army Research Laboratory
  • Class Pyridones; Small molecules
  • Mechanism of Action Immunomodulators; Type II bacterial DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Anthrax; Bacterial infections; Burkholderia infections; Ebola virus infections; Escherichia coli infections; Influenza virus infections; Methicillin-resistant Staphylococcus aureus infections; Mycoses

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Anthrax in Switzerland (PO)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Bacterial-infections in USA (PO)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Burkholderia infections in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top